Crenigacestat
Code | Size | Price |
---|
TAR-T3633-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3633-1mg | 1mg | £115.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3633-5mg | 5mg | £168.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3633-1mL | 1 mL * 10 mM (in DMSO) | £169.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3633-10mg | 10mg | £230.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3633-25mg | 25mg | £369.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
LY3039478 is an orally bioavailable Notch inhibitor with an IC50 of ~1 nM in most of the tumor cell lines tested. LY3039478 effectively inhibits mutant Notch receptor activity. In a xenograft tumor model, LY3039478 inhibited expression of Notch-regulated genes and N1ICD cleavage in the tumor microenvironment.
CAS:
1421438-81-4
Formula:
C22H23F3N4O4
Molecular Weight:
464.445
Pathway:
Neuroscience; Stem Cells; Proteases/Proteasome
Purity:
0.9876
SMILES:
C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2cccnc2N(CCO)C1=O
Target:
Gamma-secretase
References
M?emets-Allas K, et al. Biochem Biophys Res Commun. 2016 May 20;474(1):118-25.
Lu B, He Y, He J, et al. Epigenetic profiling identifies LIF as a super-enhancer controlled regulator of stem cell-like properties in osteosarcoma. Molecular Cancer Research. 2020, 18(1): 57-67
Lu B, He Y, He J, et al. Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell?like Properties in Osteosarcoma[J]. Molecular Cancer Research. 2020, 18(1): 57-67.
Bhagat TD, et al. J Biol Chem. 2017, 292(3):837-846.
Eli Lilly Company. The 8th SCI-RSC Symposium on Proteinase Inhibitor Design. 2013.
Mark H. Bender, et al. Cancer Res, 2013, 73(8 Suppl):Abstract nr 1131.